Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study
暂无分享,去创建一个
H. Kantarjian | G. Garcia-Manero | J. Cortes | S. Verstovsek | N. Daver | N. Pemmaraju | P. Bose | K. Naqvi
[1] Kuan-Der Lee,et al. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan , 2016, Hematology.
[2] H. Kantarjian,et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. , 2015, Leukemia research.
[3] N. Lavi,et al. Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. , 2015, Leukemia research.
[4] H. Kantarjian,et al. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. , 2015, Clinical lymphoma, myeloma & leukemia.
[5] Y. Saunthararajah,et al. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts , 2015, Leukemia & lymphoma.
[6] C. Harrison,et al. Combination therapy with ruxolitinib plus 5‐azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast‐phase myeloproliferative neoplasms , 2014, British journal of haematology.
[7] R. Hoffman,et al. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis , 2014, British journal of haematology.
[8] R. Mesa,et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval , 2014, Leukemia & lymphoma.
[9] Francisco Cervantes,et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.
[10] Z. Estrov,et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. , 2012, Blood.
[11] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[12] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[13] A. Tefferi,et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. Quesnel,et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). , 2010, Blood.
[15] M. Cazzola,et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.
[16] V. Najfeld,et al. Therapeutic options for patients with myelofibrosis in blast phase. , 2010, Leukemia research.
[17] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[18] S. Verstovsek,et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis , 2009, Leukemia.
[19] U. Germing,et al. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features , 2008, Leukemia.
[20] H. Kantarjian,et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis , 2008, Leukemia.
[21] P. Campbell,et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.
[22] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[23] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[24] P. Wollan,et al. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995 , 1999, American journal of hematology.